Quotient Sciences, a global pharmaceutical drug development and manufacturing accelerator, completed a U.S. FDA inspection of its bioanalytical facility in Alnwick, UK. The regulatory inspection was conducted to audit three bioequivalence studies for three different insulin analogues for a pharmaceutical company. Quotient Sciences’ Alnwick facility has specialty bioanalytical expertise and facilities for conducting bioequivalence studies, which play a crucial role in evaluating the similar...